Cell kinetic markers in cutaneous squamous and basal cell carcinoma of the head and neck

Alaeddini, Mojgan; Etemad‐Moghadam, Shahroo

doi:10.1016/j.bjorl.2020.07.010

Cited by 4 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biological behavior of tumors is substantially influenced by proliferation markers. The Ki67 nuclear antigen is primarily associated with cell proliferation and is only expressed in cycling cells [ 36 ]. Regarding normal epidermis adjacent to the tumor, we observed that the positive reaction to Ki67 was present in only a few of the keratinocytes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma

Cojocaru

Bîrjovanu²,

Ciurea³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Figure 5 -Cd44 Immunoexpression In: (A) Control; (B) Superfi...mentioning

confidence: 99%

Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma

Cojocaru

Bîrjovanu²,

Ciurea³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“…It is known that melanocytes with MC1R loss of function mutations have a decreased capacity to repair DNA damage caused by UV light, but this has yet to be shown with keratinocytes [ 39 , 40 ]. Other molecular factors that have been implicated in the pathogenesis of BCC include Wnt signaling, SOX2 , and geminin (GMNN) [ 43 , 44 , 45 ].…”

Section: Pathogenesis Of Nmscsmentioning

confidence: 99%

Management of Cutaneous Head and Neck Squamous and Basal Cell Carcinomas for Immunocompromised Patients

Bommakanti

Kosaraju

Tam

et al. 2023

Cancers

View full text Add to dashboard Cite

The incidence of non-melanoma skin cancer (NMSC) continues to rise, and more than one million cases are diagnosed in the United States each year. The increase in prevalence has been attributed to increased lifespan and improvements in survival for conditions that increase the risk of these malignancies. Patients who are immunocompromised have a higher risk of developing NMSC compared to the general population. In immunosuppressed patients, a combination of prevention, frequent surveillance, and early intervention are necessary to reduce morbidity and mortality. In this review, we collate and summarize current knowledge regarding pathogenesis of head and neck cutaneous SCC and BCC within immunocompromised patients, examine the potential role of the immune response in disease progression, and detail the role of novel immunotherapies in this subset of patients.

show abstract

“…Geminin is a multifunctional protein that plays important roles in DNA replication and transcriptional/epigenetic regulation and is frequently deregulated in human cancers. The upregulation of geminin in various malignancies was shown to be correlated with tumor cell proliferation, invasion, and metastasis ( Gonzalez et al, 2004 ; Petropoulou et al, 2008 ; Emmett and O’Shea, 2012 ; Rajan et al, 2013 ; Sato et al, 2013 ; Hills and Diffley, 2014 ; Yagi et al, 2014 ; Zhang et al, 2017 ; Ryan et al, 2019 ; Alaeddini and Etemad-Moghadam, 2020 ; Lewis and Stracker, 2021 ). Tumor cells depend on geminin to prevent excess DNA replication from triggering DNA damage–induced apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Lysophosphatidic Acid–Induced EGFR Transactivation Promotes Gastric Cancer Cell DNA Replication by Stabilizing Geminin in the S Phase

et al. 2021

View full text Add to dashboard Cite

Geminin, an inhibitor of the DNA replication licensing factor, chromatin licensing and DNA replication factor (Cdt) 1, is essential for the maintenance of genomic integrity. As a multifunctional protein, geminin is also involved in tumor progression, but the molecular details are largely unknown. Here, we found that lysophosphatidic acid (LPA)–induced upregulation of geminin was specific to gastric cancer cells. LPA acted via LPA receptor (LPAR) 3 and matrix metalloproteinases (MMPs) signaling to transactivate epidermal growth factor receptor (EGFR) (Y1173) and thereby stabilize geminin expression level during the S phase. LPA also induced the expression of deubiquitinating protein (DUB) 3, which prevented geminin degradation. These results reveal a novel mechanism underlying gastric cancer progression that involves the regulation of geminin stability by LPA-induced EGFR transactivation and provide potential targets for the signaling pathway and tumor cell–specific inhibitors.

show abstract

Cell kinetic markers in cutaneous squamous and basal cell carcinoma of the head and neck

Cited by 4 publications

References 25 publications

Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma

Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma

Management of Cutaneous Head and Neck Squamous and Basal Cell Carcinomas for Immunocompromised Patients

Lysophosphatidic Acid–Induced EGFR Transactivation Promotes Gastric Cancer Cell DNA Replication by Stabilizing Geminin in the S Phase

Contact Info

Product

Resources

About